Focusing on Clinical and Research Services

MRD

Measurable Residual Disease Moves Deeper Into Hematologic Cancer Development

Pharma's Almanac

Site Network

How Regional Sites in a Global Site Network Combine Local Insight with Global Scale

Darin Brimhall, D.O., FACP

Trialmed

Clinical Diversity

Driving Diversity and Accessibility in Clinical Trials Starts at the Community Level

Melissa Choi, M.D.

Trialmed

Pathfinder

Surrogate Endpoints vs. Clinical Endpoints: Which Evidence Strategy Is Better for Drug Development?

Nice Insight

Oncology

Harnessing Macrophage Biology to Overcome Tumor Immune Evasion

Roy Maute, Ph.D.; David Alvaro, Ph.D.

Pheast Therapeutics

Pathfinder

Basket vs. Umbrella Clinical Trials: Which Precision Oncology Trial Design Is Better?

Nice Insight

Pathfinder

Adaptive Trials vs. Traditional Randomized Controlled Trials: Which Clinical Trial Design Is Better?

Nice Insight

Basket Trials

Basket Trials and the Future of Rare Cancer Research

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Site-Based vs. Decentralized vs. Hybrid Clinical Trials: Which Model Is Best for Modern Clinical Research?

Nice Insight

Adaptive Trials

Designing for Change: Adaptive Clinical Trials and the Evolving Path to Regulatory Acceptance

Pharma's Almanac

Expedited Pathways

Accelerated Pathways: Are They Delivering on Their Promise?

David Alvaro, Ph.D.

Pharma's Almanac